Alexandria Venture Investments and Biomed Realty Ventures were among the investors as the immunotherapy developer closed the round's final tranche.

US-based immunotherapy developer Compass Therapeutics closed a series A round featuring life sciences real estate providers Biomed Realty and Alexandria Real Estate Equities at $132m yesterday.

Investment firm OrbiMed Advisors led the round, which was also backed by F-Prime Capital, part of investment and financial services group Fidelity, as well as Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Ulysses Holdings and Borealis Ventures.

The round was closed after Compass secured the $49m final tranche. Biomed and Alexandria participated through their…